https://www.phoremost.com2025-11-12T16:36:34+00:00https://www.phoremost.com/about2025-11-12T16:36:34+00:00https://www.phoremost.com/science2025-11-12T16:36:34+00:00https://www.phoremost.com/partnering2025-11-12T16:36:34+00:00https://www.phoremost.com/join-us2025-11-12T16:36:34+00:00https://www.phoremost.com/news2025-11-12T16:36:34+00:00https://www.phoremost.com/news/phoremost-and-the-wistar-institute-collaborate-to-identify-new-druggable-targets-in-cancer-immunotherapy-and-aging2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-ltd-and-university-of-cambridge-collaborate-to-identify-innovative-drug-targets-for-neurodegenerative-disease2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-babraham-institute-awarded-0-6m-innovate-uk-funding2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-sixth-element-capital-announce-creation-and-investment-in-neophore-an-immuno-oncology-company2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-plexxikon-collaborate-to-identify-novel-drug-targets2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-neophore-receive-innovate-uk-funding-to-support-development-of-a-novel-small-molecule-cancer-immunotherapy-programme2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-completes-15m-11m-series-a-round-to-enter-drug-discovery2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-o2h-discovery-collaborate-to-progress-first-in-class-drug-discovery-programs2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-ligand-subsidiary-vernalis-limited-announce-drug-discovery-collaboration-for-novel-oncology-target2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-c4x-discovery-announce-neurodegeneration-focused-drug-discovery-collaboration2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-instem-enter-structural-biology-alliance2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-appoints-dr-lorenz-mayr-as-non-executive-director2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-named-biotech-company-of-the-year-at-cambridge-independent-science-and-technology-awards-20192022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-sentinel-oncology-expand-collaboration-to-jointly-accelerate-novel-glioma-therapeutic-through-preclinical-development2022-10-04T12:58:47+00:00https://www.phoremost.com/news/elrig-drug-discovery2022-10-04T12:58:47+00:00https://www.phoremost.com/news/bio-europe2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-boehringer-ingelheim-enter-multi-project-drug-discovery-collaboration2022-10-04T12:58:47+00:00https://www.phoremost.com/news/jp-morgan-annual-healthcare-conference2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-enters-multi-project-drug-discovery-collaboration-with-otsuka-pharmaceutical2022-10-04T12:58:47+00:00https://www.phoremost.com/news/slas2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-strengthens-leadership-team-with-two-key-appointments2022-10-04T12:58:47+00:00https://www.phoremost.com/news/drug-discovery-world-feature-article-target-discovery-and-drug-development-what-comes-after-crispr2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-xtalpi-sign-ai-based-pharmaceutical-drug-discovery-collaboration-agreement2022-10-04T12:58:47+00:00https://www.phoremost.com/news/3rd-targeted-protein-degradation-tpd-summit2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-oxford-biomedica-enter-gene-therapy-discovery-collaboration2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-closes-33m-46m-series-b-financing2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-appoints-christian-dillon-as-vice-president-of-biology2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-and-polarisqb-announce-a-multi-target-collaboration-to-investigate-next-generation-cancer-therapies2022-10-04T12:58:47+00:00https://www.phoremost.com/news/neocura-and-phoremost-announce-research-collaboration-to-explore-novel-cancer-therapeutics2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-expands-into-new-facility-at-unity-campus-cambridge-uk2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-promotes-dr-neil-torbett-to-chief-executive-officer2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-enters-multi-project-drug-target-discovery-collaboration-with-roche2022-10-04T12:58:47+00:00https://www.phoremost.com/news/phoremost-enters-multi-target-collaboration-with-targeted-protein-degradation-leader-arvinas2022-10-28T07:37:35+00:00https://www.phoremost.com/news/phoremost-and-thinkcyte-collaborate-to-advance-ai-based-drug-discovery2022-12-14T11:59:38+00:00https://www.phoremost.com/news/phoremost-reaches-milestone-in-a-target-discovery-alliance-with-boehringer-ingelheim2023-01-05T08:36:10+00:00https://www.phoremost.com/news/phoremost-appoints-professor-peter-parker-and-dr-jason-imbriglio-to-scientific-advisory-board2023-07-17T08:00:42+00:00https://www.phoremost.com/news/phoremost-introduces-glueseeker-platform-for-discovery-of-molecular-glue-degraders2024-05-21T08:00:58+00:00https://www.phoremost.com/news/phoremost-achieves-second-milestone-in-target-discovery-alliance-with-boehringer-ingelheim2024-06-03T08:38:47+00:00https://www.phoremost.com/news/phoremost-extends-series-b-financing-to-50m-to-advance-high-value-oncology-and-inflammation-degrader-programmes2024-09-10T07:23:15+00:00https://www.phoremost.com/news/phoremost-makes-key-appointments-to-board-to-advance-development-of-next-generation-degrader-therapeutics2025-05-07T07:57:21+00:00https://www.phoremost.com/news/phoremost-demonstrates-new-approach-to-rationalise-molecular-glue-drug-discovery2025-07-22T07:54:07+00:00https://www.phoremost.com/news/phoremost-appoints-dr-adam-gilbert-to-scientific-advisory-board2025-07-28T07:14:45+00:00https://www.phoremost.com/contact2025-11-12T16:36:34+00:00https://www.phoremost.com/blog2025-11-12T16:36:34+00:00https://www.phoremost.com/blog/drugging-the-undruggable-phoremost-is-coming-of-age-to-meet-key-industry-challenges2022-10-04T12:58:47+00:00https://www.phoremost.com/blog/artificial-intelligence-a-revolution-in-drug-discovery2022-10-04T12:58:47+00:00https://www.phoremost.com/blog/expanding-the-druggable-toolbox-improving-access-to-undruggable-targets2022-10-04T12:58:47+00:00https://www.phoremost.com/blog/phoremosts-experience-of-innovate-uk-s-biomedical-catalyst-grant2022-10-04T12:58:47+00:00https://www.phoremost.com/blog/phorest-and-green-impact-the-path-to-a-gold-award2022-10-04T12:58:47+00:00https://www.phoremost.com/blog/2023-phoremost-s-year-of-drugging-the-undruggable2023-12-20T11:09:34+00:00https://www.phoremost.com/blog/phoremost-meet-the-team-rich-boyce-senior-vp-drug-discovery2024-04-29T09:17:11+00:00https://www.phoremost.com/blog/phoremost-meet-the-team-dr-darcie-mulhearn-team-leader-target-discovery2024-06-05T13:15:31+00:00https://www.phoremost.com/blog/phoremost-meet-the-team-dr-jia-lu-principal-scientist-target-discovery2024-08-12T13:53:04+00:00https://www.phoremost.com/blog/phoremost-meet-the-team-ash-sundaresh-team-leader-drug-discovery2025-01-27T10:07:24+00:00